Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620430 | 0.92 | QPCT (0.43) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL12371718 | 0.87 | POLB (0.41) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL13608435 | 0.85 | FGFR1 (0.45) | FGFR1SRCPOLBALOX15TSHR | |
| SCHEMBL13620265 | 0.82 | POLB (0.44) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL13608370 | 0.80 | TBXAS1 (0.43) | FGFR1SRCPOLB | |
| SCHEMBL12371788 | 0.80 | POLB (0.44) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL13620406 | 0.79 | POLB (0.41) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL12371799 | 0.78 | SMN1; SMN2 (0.43) | POLBALOX15TSHRHTTSMN1; SMN2 | |
| SCHEMBL12371666 | 0.77 | JAK2 (0.44) | — | |
| SCHEMBL13620251 | 0.76 | JAK2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | FGFR1 4175/4885SRC 670/4885POLB 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.